Key Terms & Concepts — UPSC Mains
GLP-1 Receptor Agonist
"A drug class mimicking the gut hormone GLP-1 to stimulate insulin release and reduce appetite, approved first for type 2 diabetes and later for weight loss, now central to India's dual-use drug-access policy debate."
GLP-1 receptor agonists are a class of drugs, including semaglutide, that mimic glucagon-like peptide-1 (GLP-1), a naturally occurring gut hormone. They stimulate insulin secretion after meals, slow gastric emptying, and increase satiety. The class was developed and first approved for managing type 2 diabetes, where trial evidence has also shown meaningful cardiovascular and mortality benefits beyond blood-sugar control alone. Because the same appetite-suppressing mechanism that helps regulate blood sugar also reduces food intake generally, GLP-1 drugs have since been separately approved and widely marketed for weight loss, creating a second, much larger and higher-willingness-to-pay market beyond the diabetic population the drugs were originally developed for. This dual approval creates a specific policy problem for health-access design: left to an unrestricted market, subsidised or insurance-linked access tends to flow toward the weight-loss indication among wealthier patients rather than toward the diabetic population with the strongest clinical justification and often the least ability to pay. In India, where the ICMR-INDIAB study estimates 101 million people live with diabetes and a further 136 million are prediabetic, this has prompted proposals for a phased, eligibility-criteria-based rollout, prioritising diabetes and cardiovascular-risk patients, rather than an immediate unrestricted national rollout.
A live health-policy case testing whether a candidate can analyse access-prioritisation for a dual-use technology, a recurring GS2/GS3 pattern applicable well beyond this one drug class.
- 1 Drug class mimicking the gut hormone GLP-1 (glucagon-like peptide-1)
- 2 Mechanism: stimulates insulin secretion, slows gastric emptying, increases satiety
- 3 First approved for type 2 diabetes management; later approved for weight loss
- 4 ICMR-INDIAB study: 101 million diabetic, 136 million prediabetic Indians
- 5 Dual approval creates an access-prioritisation problem between diabetic and weight-loss demand
- 6 Proposed Indian policy response: phased, criteria-based rollout in select states before national scale-up
- 7 Illustrates the general 'need versus willingness-to-pay' access-design problem for dual-use health technologies
Indu Bhushan's proposal for a four- or five-state pilot with strict eligibility criteria aimed to ensure GLP-1 access reached diabetic and cardiovascular-risk patients first, rather than being captured by wealthier weight-loss demand.
